BR9911151A - Inibidores do fator de transcrição nf-kb - Google Patents

Inibidores do fator de transcrição nf-kb

Info

Publication number: BR9911151A
Authority: BR; Brazil
Prior art keywords: sym; transcription factor; present; diseases; disease
Prior art date: 1998-06-19

Application number

BR9911151-9A

Other languages

English (en)

Portuguese (pt)

Inventor

James F Callahan

Marie C Chabot-Fletcher

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-19

Filing date

1999-06-18

Publication date

2001-03-06

1999-06-18 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2001-03-06 Publication of BR9911151A publication Critical patent/BR9911151A/pt

Links

102000040945 Transcription factor Human genes 0.000 title abstract 3
108091023040 Transcription factor Proteins 0.000 title abstract 3
239000003112 inhibitor Substances 0.000 title abstract 3
201000010099 disease Diseases 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
230000004913 activation Effects 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
208000017520 skin disease Diseases 0.000 abstract 2
MFWNULQJIPYQAD-UHFFFAOYSA-N 2-amino-2,3-dihydroinden-1-one Chemical compound C1=CC=C2C(=O)C(N)CC2=C1 MFWNULQJIPYQAD-UHFFFAOYSA-N 0.000 abstract 1
208000030507 AIDS Diseases 0.000 abstract 1
208000024827 Alzheimer disease Diseases 0.000 abstract 1
206010003210 Arteriosclerosis Diseases 0.000 abstract 1
206010003594 Ataxia telangiectasia Diseases 0.000 abstract 1
208000017604 Hodgkin disease Diseases 0.000 abstract 1
208000010747 Hodgkins lymphoma Diseases 0.000 abstract 1
208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
208000036142 Viral infection Diseases 0.000 abstract 1
230000001154 acute effect Effects 0.000 abstract 1
208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
230000005784 autoimmunity Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
150000004677 hydrates Chemical class 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
210000000056 organ Anatomy 0.000 abstract 1
201000008482 osteoarthritis Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
230000009385 viral infection Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Toxicology (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Urology & Nephrology (AREA)
AIDS & HIV (AREA)

BR9911151-9A 1998-06-19 1999-06-18 Inibidores do fator de transcrição nf-kb BR9911151A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9001698P	1998-06-19	1998-06-19
PCT/US1999/013897 WO1999065495A1 (en)	1998-06-19	1999-06-18	INHIBITORS OF TRANSCRIPTION FACTOR NF-λB

Publications (1)

Publication Number	Publication Date
BR9911151A true BR9911151A (pt)	2001-03-06

Family

ID=22220761

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9911151-9A BR9911151A (pt)	1998-06-19	1999-06-18	Inibidores do fator de transcrição nf-kb

Country Status (17)

Country	Link
EP (1)	EP1085872A4 (cs)
JP (1)	JP2002518333A (cs)
KR (1)	KR20010052990A (cs)
CN (1)	CN1306428A (cs)
AR (1)	AR019871A1 (cs)
AU (1)	AU4699699A (cs)
BR (1)	BR9911151A (cs)
CA (1)	CA2335293A1 (cs)
CO (1)	CO5080752A1 (cs)
CZ (1)	CZ20004760A3 (cs)
HU (1)	HUP0102492A2 (cs)
IL (1)	IL140324A0 (cs)
NO (1)	NO20006452L (cs)
PL (1)	PL345577A1 (cs)
TR (1)	TR200003779T2 (cs)
WO (1)	WO1999065495A1 (cs)
ZA (1)	ZA200007448B (cs)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999058674A2 (en)	1998-05-14	1999-11-18	Immunex Corporation	Method of inhibiting osteoclast activity
ATE497001T1 (de)	1996-12-23	2011-02-15	Immunex Corp	Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
US6316408B1 (en)	1997-04-16	2001-11-13	Amgen Inc.	Methods of use for osetoprotegerin binding protein receptors
AU2968701A (en) *	2000-01-24	2001-07-31	Genzyme Corporation	Jak/stat pathway inhibitors and the uses thereof
US20060148732A1 (en) *	2000-11-17	2006-07-06	Gutterman Jordan U	Inhibition of NF-kappaB by triterpene compositions
TR201809678T4 (tr)	2001-06-26	2018-07-23	Amgen Fremont Inc	Opgl ye karşi antikorlar.
US7425580B2 (en)	2004-05-19	2008-09-16	Wyeth	(Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
WO2007097981A2 (en)	2006-02-16	2007-08-30	Millennium Pharmaceuticals, Inc.	Alpha carbolines and uses thereof
EP2366699B1 (en)	2008-10-02	2013-08-07	Asahi Kasei Pharma Corporation	8-substituted isoquinoline derivative and use thereof
WO2010108058A2 (en)	2009-03-20	2010-09-23	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Small molecule inhibitors of dusp6 and uses therefor
US9186365B2 (en) *	2009-07-31	2015-11-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antiangiogenic small molecules and methods of use
WO2012109527A2 (en)	2011-02-10	2012-08-16	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Class of hdac inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
US9670236B2 (en)	2012-10-31	2017-06-06	University of Pittsburgh—of the Commonwealth System of Higher Education	Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury

1998
- 1998-06-18 HU HU0102492A patent/HUP0102492A2/hu unknown
1999
- 1999-06-17 CO CO99037918A patent/CO5080752A1/es unknown
- 1999-06-18 JP JP2000554375A patent/JP2002518333A/ja not_active Withdrawn
- 1999-06-18 AR ARP990102952A patent/AR019871A1/es unknown
- 1999-06-18 AU AU46996/99A patent/AU4699699A/en not_active Abandoned
- 1999-06-18 CN CN99807572A patent/CN1306428A/zh active Pending
- 1999-06-18 PL PL99345577A patent/PL345577A1/xx not_active Application Discontinuation
- 1999-06-18 BR BR9911151-9A patent/BR9911151A/pt not_active Application Discontinuation
- 1999-06-18 CZ CZ20004760A patent/CZ20004760A3/cs unknown
- 1999-06-18 WO PCT/US1999/013897 patent/WO1999065495A1/en not_active Ceased
- 1999-06-18 TR TR2000/03779T patent/TR200003779T2/xx unknown
- 1999-06-18 EP EP99930459A patent/EP1085872A4/en not_active Withdrawn
- 1999-06-18 IL IL14032499A patent/IL140324A0/xx unknown
- 1999-06-18 KR KR1020007014385A patent/KR20010052990A/ko not_active Withdrawn
- 1999-06-18 CA CA002335293A patent/CA2335293A1/en not_active Abandoned
2000
- 2000-12-13 ZA ZA200007448A patent/ZA200007448B/en unknown
- 2000-12-18 NO NO20006452A patent/NO20006452L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
PL345577A1 (en)	2001-12-17
TR200003779T2 (tr)	2001-06-21
IL140324A0 (en)	2002-02-10
CN1306428A (zh)	2001-08-01
AU4699699A (en)	2000-01-05
ZA200007448B (en)	2001-12-12
NO20006452D0 (no)	2000-12-18
EP1085872A1 (en)	2001-03-28
KR20010052990A (ko)	2001-06-25
CZ20004760A3 (cs)	2001-08-15
JP2002518333A (ja)	2002-06-25
CO5080752A1 (es)	2001-09-25
AR019871A1 (es)	2002-03-20
EP1085872A4 (en)	2003-04-16
HUP0102492A2 (hu)	2001-11-28
NO20006452L (no)	2001-02-16
CA2335293A1 (en)	1999-12-23
WO1999065495A1 (en)	1999-12-23

Legal Events

Date	Code	Title	Description
2003-12-09	FA10	Dismissal: dismissal - article 33 of industrial property law
2004-07-27	B11Y	Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]

Publication	Publication Date	Title
WO1999065449A3 (en)	2000-03-30	INHIBITORS OF TRANSCRIPTION FACTOR NF-λB
CY1109045T1 (el)	2014-07-02	Ρετινοειδη για τη θεραπεια του εμφυσηματος
DE60233239D1 (de)	2009-09-17	Benzothiazepinderivate
ATE361300T1 (de)	2007-05-15	Derivate von heteroarylnitrilverbindungen
ATE441654T1 (de)	2009-09-15	Edg-rezeptoragonisten
NO20040954L (no)	2004-03-04	Benzotiazepinderivater for behandling av hyperlipidemi
BR0215240A (pt)	2004-10-26	Derivados de calcona e seu uso no tratamento de doenças
PL369108A1 (en)	2005-04-18	17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
ECSP044998A (es)	2004-04-28	Pirrolo pirimidinas como agentes para la inhibicion de proteasas de cisteina
IS6852A (is)	2003-06-18	Efnasambönd
PT1292594E (pt)	2004-12-31	Derivados de quinazolina para o tratamento de tumores
IS6727A (is)	2003-02-24	Bíhringtengd pýrrólýlamíð sem glúkógenfosfórýlasahemlar
ATE409480T1 (de)	2008-10-15	Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
BRPI0111140B8 (pt)	2021-05-25	forma polimórfica, uso da mesma, e, composição farmacêutica
ATE386725T1 (de)	2008-03-15	Heterocyclylverbindungen
BR0005616A (pt)	2001-07-17	2-(3,5-bis-trifluormetil-fenil)-n-metil-n-(6-morfolin-4-i l-4-o-tolil-piridin-3-il)-isobutiramida
BR0312780A (pt)	2005-05-03	Compostos de tiofeno-carboxamida substituìda para o tratamento de inflamação
ATE403428T1 (de)	2008-08-15	Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
HUP0402577A2 (hu)	2005-03-29	Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra
MY133512A (en)	2007-11-30	Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors
TR200101163T2 (tr)	2001-08-21	Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları
PT1268472E (pt)	2005-01-31	Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
NO20006452L (no)	2001-02-16	Inhibitorer av transkripsjonsfaktor NF-kB
DE60015508T2 (de)	2005-04-21	C-16 ungesätigte fp-selektive prostaglandin analoge
TR199801614T2 (xx)	1998-11-23	Peptit t�revleri